Women of childbearing age who are hepatitis B patients and carriers can get pregnant and have children as planned under the guidance of a doctor, but there is a concern that the mother is a hepatitis B patient or a carrier of the virus and the child born will be a hepatitis B patient. That is, mother-to-child transmission. In fact, with maternal prenatal screening and combined active and passive immunization of the infant has greatly reduced the rate of hepatitis B virus infection. However, it is important to recognize that: 1. Without immunoprophylaxis, up to 90% of infants born to HBeAg-positive mothers may become infected with hepatitis B virus. With appropriate prophylaxis: hepatitis B immunoglobulin (HBIG) and hepatitis B vaccination, the risk of mother-to-child transmission still exists, especially in mothers with high viral load and HBeAg-positive status, and the risk of transmission of hepatitis B virus from mothers with high viral load is as high as 28%. Therefore, active pregnancy is not recommended for women of childbearing age with high viral load. 2. Pregnant women with hepatitis B and hepatitis B virus are more likely to have complications such as premature rupture of membranes, hypertension, fetal distress, preterm delivery, postpartum hemorrhage, and gestational diabetes than normal pregnant women. During pregnancy, significant abnormalities in liver function, jaundice and ultrasound may occur. Therefore, for female hepatitis B patients and carriers, they should pay attention to liver function tests, hepatitis B virology tests, abdominal ultrasound tests, active treatment and prevention of complications, interruption of vertical transmission from mother to child, and minimizing the occurrence of pregnancy complications during pregnancy. 4, in the hepatitis B antiviral drugs, tebivudine has a specific and potent inhibitory effect on HBV, it is the only nucleoside ( acid ) analogues currently on the market by the U.S. FDA designated as pregnancy class B drugs, toxicological studies have shown that it is not carcinogenic, not teratogenic, not mutagenic, and not mitochondrial toxicity. Therefore, for patients who need antiviral therapy during pregnancy, tibivudine is preferred.